Heart failure & cardiomyopathiesSecondary analysis
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension
- Secondary analysis of the EXPLORER-HCM randomised trial
- post hoc
- exploratory
Authors' conclusion
The clinical benefits of mavacamten in symptomatic, obstructive HCM were similar in patients with and without HTN, despite differences in baseline characteristics.
Study context
- Population
- Patients with symptomatic obstructive hypertrophic cardiomyopathy
- Participants
- 251 patients
- Comparison
- Mavacamten vs placebo in patients with vs without hypertension
- Hypertension (HTN)n = 119
Primary result
As reported in the abstract
- Mavacamten improved all primary, secondary and exploratory endpoints regardless of HTN status or mean systolic blood pressure (SBP)
- post hoc exploratory analysis
Further findings
Baseline characteristics, HTN vs no HTN · HTN: more comorbidities
SBP HTN 134 ± 15.1 mm Hg · No HTN 123 ± 13.8 mm Hg
Peak oxygen consumption HTN 19 ± 3 mL/kg/min · No HTN 20 ± 4 mL/kg/min
NYHA class II HTN 72% · No HTN 73%
Valsalva LVOT gradient HTN 72 ± 34 mm Hg · No HTN 74 ± 30 mm Hg
KCCQ-Clinical Summary Score HTN 70.6 ± 18.8 · No HTN 68.9 ± 23.1
NT-proBNP (geometric mean) HTN 632 ± 129 pg/mL · No HTN 745 ± 130 pg/mL
- Baseline characteristics, HTN vs no HTN: Age P < 0.001
- Baseline characteristics, HTN vs no HTN: SBP P < 0.001
- Baseline characteristics, HTN vs no HTN: Peak oxygen consumption P = 0.021
- Baseline characteristics, HTN vs no HTN: HTN: 60 mavacamten, 59 placebo
Original publication
Summarised from the published abstract; every number is checked against it